期刊文献+

尼美舒利胶囊剂的制备和质量控制 被引量:2

原文传递
导出
摘要 目的:制备尼美舒利胶囊剂并建立其质量标准。方法:考察填充剂和润滑剂对尼美舒利胶囊内容物流动性的影响,采用单因素试验优化尼美舒利胶囊剂处方,测定溶出度,进行含量测定的分析方法验证。结果:加入预胶化淀粉(62.7%)和微粉硅胶(4%)制得的尼美舒利胶囊剂囊内容物流动性良好,溶出均一性、溶出重复性,含量测定合格。结论:获得的尼美舒利胶囊剂的处方工艺适合产业化,建立的质量标准能够控制产品质量。
作者 张辉
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第5期393-395,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献4

二级参考文献43

  • 1Vame J R. Inhibitiong of prostaglandin synthesis as a mechanism of action for aspirin - like drugs. Nature New Biol, 1971,231(19) :232
  • 2Clive D M, Stoff J S. Renal Syndromes Associated with Nonsteroidal Antiinflammatory Drugs. N Engl J Med. 1984,310:563
  • 3Pirson Y, Van Ypersele de Strihou C. Renal Side Effects of Nonsteroidal Anti - Inflammatory Drugs. Clinical Relevance. Am J kidney Dis. 1986,8:337
  • 4Mitclell A, Akarasereenont P, Thiermann C, et al. Selectivity of ninsteroidal anti- inflammatory drugs as inhibitors of constitutive and inducible cycloxygenase. Pro NaH Acal Sci USA, 1993,90 (24): 11693
  • 5Vane J R. Towards a better aspirin. Nature, 1994,36(2) :215
  • 6Piecot D,loll P J .Garaavito R M. The X - ray crystal structure of the membrane protein prostaglandin H2 synthase - 1. Nature, 1994,367(6460) :243
  • 7Groosman c G,Wiseman J, et al. Inhibition of COX - 1 and COX - 2 in human platelects and mononuclear cell by NSAIDS. Inflamm Res,1995,44(Suppl 3) :S272
  • 8Gans k P, Anti - inflammatory and safety profile of Dup - 697. J Pharmacol Exp Ther. 1990,254( 1 ): 180
  • 9Anon. First approval of celecoxib in US. Scrip, 1999, (2400): 18
  • 10Thomas D, Penning, John J. Talloy, et al. Synthesis and Biological Evaluation of the 1,5 - Diarylpyrazole Class of Cyclooxygenase - 2 Inhibitors: Identification of 4- [5 - (4 - Methylphenyl) - 3 - (trifluormethyl) - 1 H - pyrazol - 1 - yl] benzenesulfonamide (Celecoxib). J Med Chem, 1997,40:13471365

共引文献22

同被引文献18

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部